This company listing is no longer active
SENS Stock Overview
Sensyne Health plc, a healthcare technology company, develops software products that connects healthcare professionals with patients in the United Kingdom and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Sensyne Health plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0035 |
| 52 Week High | UK£1.55 |
| 52 Week Low | UK£0.0016 |
| Beta | 1.2 |
| 1 Month Change | -71.43% |
| 3 Month Change | -96.74% |
| 1 Year Change | -99.75% |
| 3 Year Change | -99.72% |
| 5 Year Change | n/a |
| Change since IPO | -99.81% |
Recent News & Updates
Shareholder Returns
| SENS | GB Healthcare Services | GB Market | |
|---|---|---|---|
| 7D | -53.3% | 5.3% | 1.0% |
| 1Y | -99.8% | 32.9% | 3.0% |
Return vs Industry: SENS underperformed the UK Healthcare Services industry which returned -18.5% over the past year.
Return vs Market: SENS underperformed the UK Market which returned -8.6% over the past year.
Price Volatility
| SENS volatility | |
|---|---|
| SENS Average Weekly Movement | 32.5% |
| Healthcare Services Industry Average Movement | 8.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: SENS's share price has been volatile over the past 3 months.
Volatility Over Time: SENS's weekly volatility has increased from 20% to 32% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 158 | Alex Snow | www.sensynehealth.com |
Sensyne Health plc, a healthcare technology company, develops software products that connects healthcare professionals with patients in the United Kingdom and the United States. Its products include CVm-Health, a web-based application for Covid-19 self-monitoring; DBm-Health, a patient to clinician system that allows health care professionals manage patients with diabetes; GDm-Health, a prescribed digital therapeutic for remote management of diabetes in pregnancy; and BPm-Health that allows pregnant women to self-monitor blood pressure during pregnancy. The company’s products also include MagnifEye that allows reading and analysis of diagnostic tests; SEND, an evidence-based digital charting system for vital-signs observations; EDGE, a prescribed digital therapeutic for monitoring chronic obstructive pulmonary disease at home; CleanSpace, a system for monitoring personal exposure to air pollution; Support-HF, a prescribed digital therapeutic for monitoring heart failure at home; Sense, a clinical AI algorithm engine; SYNE-COV, a COVID-19 patient outcome algorithm; and SYNE-OPS, a real-time operational patient management algorithm.
Sensyne Health plc Fundamentals Summary
| SENS fundamental statistics | |
|---|---|
| Market cap | UK£582.63k |
| Earnings (TTM) | -UK£34.83m |
| Revenue (TTM) | UK£7.81m |
0.1x
P/S Ratio0.0x
P/E RatioIs SENS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SENS income statement (TTM) | |
|---|---|
| Revenue | UK£7.81m |
| Cost of Revenue | UK£2.78m |
| Gross Profit | UK£5.03m |
| Other Expenses | UK£39.86m |
| Earnings | -UK£34.83m |
Last Reported Earnings
Oct 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 64.37% |
| Net Profit Margin | -446.13% |
| Debt/Equity Ratio | 0% |
How did SENS perform over the long term?
See historical performance and comparison